Abstract 2234P
Background
Immune checkpoint inhibitors (ICIs) can induce dramatic anti-tumor immune responses as well as significant immune-related adverse events (irAEs). While the drivers of irAEs are poorly understood, we hypothesized that inflammation against infiltrating tumor cells could result in local inflammation or a break in immune tolerance that drive a subset of irAEs in the infiltrated organ.
Methods
The medical records of cancer patients admitted to the Massachusetts General Hospital with concern for an irAE from Feb 2011 - Nov 2021 were reviewed for radiographic evidence of metastatic or primary tumors in the liver and/or lungs and a diagnosis of irHepatitis and/or irPneumonitis during admission. Cases with radiation to the irAE organ in the prior year were excluded. Multivariable analysis using logistic regression was used to obtain the odds ratios of irAEs in tumor-bearing organs. Pathology specimens of irAE tissues were reviewed for histologic evidence of tumor cells.
Results
384 hospitalized patients were identified (irHepatitis n=41, irPneumonitis n=30) (Table 2234P). Tumor-bearing liver was associated with irHepatitis (OR 2.4, 95% CI [1.2, 4.7], p = 0.011), even after considering only biopsy-proven cases of irHepatitis (n = 34, OR 2.6, 95% CI [1.2, 5.4], p = 0.0093). Tumor-bearing lungs were also associated with irPneumonitis (OR 2.6, 95% CI [1.1-6.6], p = 0.034). Both associations remained significant after adjusting for dual ICI use. Four cases from patients with irAEs further identified histological evidence of radiographically occult metastases in organs with irAEs. T-cell receptor sequencing of irAEs in tumor-bearing organs will be used to further define immunologic features of these irAEs. Table: 2234P
Patients with tumor-bearing organs and irAEs
Tumor-bearing liver | irHepatitis | ||
- | + | Total | |
- | 271 | 25 | 296 |
+ | 72 | 16 | 88 |
Total | 343 | 41 | 384 |
Tumor-bearing lung | irPneumonitis | ||
- | + | Total | |
- | 152 | 7 | 159 |
+ | 194 | 23 | 217 |
Total | 346 | 30 | 376* |
*8 cases were excluded due to recent lung irradiation |
Conclusions
In a pan-cancer cohort, radiographic evidence of tumor infiltration in the lung or liver is a risk factor for the development of irAEs in that same organ. Tumor infiltration may increase the risk for developing an irAEs in that organ, and these cases may have distinct molecular and clinical features.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.M. Blum: Financial Interests, Personal, Stocks or ownership: 76 Bio, Kronos Bio, Allogene Therapeutics; Financial Interests, Personal, Speaker, Consultant, Advisor: Two River Consulting, Third Rock Ventures. L. Zubiri: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Merck. D.A. Zlotoff: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, Freeline Therapeutics, Intrinsic Imaging. D. Juric: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, Genentech, Syros, Eisai, Vibliome, Mapkure, Relay Therapeutics, PIC Therapeutics; Financial Interests, Institutional, Research Funding: Novartis, Genentech, Syros, Eisai, Pfizer, Takeda, Ribon Therapeutics, Infinity, nventisBio 9RF, Cyteir, Blueprint, Arvinas. M. Dougan: Financial Interests, Personal, Speaker, Consultant, Advisor: ORIC Pharmaceuticals, Genentech, Sorriso Pharmaceuticals, Generate Biomedicines, Aditum, Palleon, Mallinckrodt Pharmaceuticals, Foghorn Therapeutics, Partner Therapeutics, SQZ Biotech, AzurRx, Moderna, Neoleukin Therapeutics, Veravas, Cerberus Therapeutics, Eli Lilly; Non-Financial Interests, Institutional, Research Grant: Eli Lilly. A. Villani: Financial Interests, Personal, Speaker, Consultant, Advisor: to Bristol Myers Squibb. K.L. Reynolds: Financial Interests, Personal, Advisory Board: SAGA Diagnostics; Financial Interests, Personal, Speaker, Consultant, Advisor: CME Outfitters, Medscape; Non-Financial Interests, Institutional, Research Funding: Bristol Myers Squibb. M. Mino-Kenudson: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Sanofi, Jansenn Oncology, Innate; Financial Interests, Personal, Royalties: Elsevier. R.J. Sullivan: Financial Interests, Personal, Advisory Board: Merck, Novartis, Bristol Myers Squibb, Eisai, Iovance, OncoSec, Pfizer, Replimune, Marengo; Financial Interests, Personal, Royalties: Up-To-Date; Financial Interests, Institutional, Research Grant: Merck; Financial Interests, Institutional, Local PI: GSK, Sanofi, Moderna, Biomed Valley Discoveries, Astex, Compugen, Beigene, Novartis, Rubius, Alkermes, Synthekine; Financial Interests, Institutional, Coordinating PI: Pfizer, Roche-Genentech, Simcha Therapeutics, OnKure, Marengo. All other authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07